Gene engineering tool provider Inscripta has grown its series C round to almost $106m, securing the extra capital from existing backers such as Mérieux Développement.
US-based gene editing technology provider Inscripta added $20m yesterday to a series C round featuring medical technology holding company Institut Mérieux that is now sized at approximately $106m.
Institut Mérieux vehicle Mérieux Développement produced the funding together with venture capital firms Venrock, Foresite, Paladin Capital Group, MLS Capital and NanoDimension.
Inscripta supplies tools such as instruments, reagents and software in addition to specialised enzymes, that help make the gene-editing process more precise and rapid. It has now raised almost $135m…
